|
GOLGB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.65390000162714E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11800000002216E-06 |
| Normal-vs-Stage2 |
1.041550E-02 |
| Normal-vs-Stage3 |
2.21369999997556E-07 |
| Normal-vs-Stage4 |
2.44810000049611E-07 |
| Stage1-vs-Stage2 |
2.132600E-01 |
| Stage1-vs-Stage3 |
3.097600E-01 |
| Stage1-vs-Stage4 |
1.063220E-01 |
| Stage2-vs-Stage3 |
6.483800E-02 |
| Stage2-vs-Stage4 |
3.323900E-02 |
| Stage3-vs-Stage4 |
5.685600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.92960000387077E-08 |
| Normal-vs-AfricanAmerican |
6.972200E-02 |
| Normal-vs-Asian |
1.69357999999509E-05 |
| Caucasian-vs-AfricanAmerican |
9.888300E-02 |
| Caucasian-vs-Asian |
6.064800E-01 |
| AfricanAmerican-vs-Asian |
6.354000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.02349999997475E-06 |
| Normal-vs-Female |
3.09559999966957E-07 |
| Male-vs-Female |
8.029200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.76850000002771E-06 |
| Normal-vs-Age(41-60Yrs) |
3.74440000006082E-07 |
| Normal-vs-Age(61-80Yrs) |
3.80330000000484E-05 |
| Normal-vs-Age(81-100Yrs) |
1.535530E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.973800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.742000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.541000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.294200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.802000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.531200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.550200E-02 |
| Classical-VS-Follicular |
6.300000E-01 |
| Classical-VS-Other |
1.792820E-01 |
| Classical-VS-Normal |
1.64250000000976E-06 |
| Tall-VS-Follicular |
1.041400E-01 |
| Tall-VS-Other |
7.712000E-01 |
| Tall-VS-Normal |
1.76809999996586E-06 |
| Follicular-VS-Other |
3.502800E-01 |
| Follicular-VS-Normal |
1.801430E-04 |
| Other-VS-Normal |
3.802400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21509999995162E-06 |
| Normal-vs-N1 |
7.04999999490141E-08 |
| N0-vs-N1 |
7.016100E-02 |
|
|
